Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Medicine (Baltimore) ; 95(4): e2237, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26825878

RESUMO

In this study, we aimed to compare the clinical efficacy of liposomal albendazole (L-ABZ) and tablet-albendazole (T-ABZ) for the treatment of human hepatic cystic echinococcosis (CE). Sixty patients with single cyst (CE1) or daughter cyst (CE2) were included in this study and were nonrandomly divided into the L-ABZ group (n = 30, 10  mg/kg per day, p.o., b.i.d.) and T-ABZ group (n = 30, 12-20 mg/kg per day, p.o., b.i.d.), respectively. The treatment duration lasted for 6 months, during which dynamic follow-up was carried out to evaluate the clinical efficacy through calculating the total effective rates (TERs). Measurement data and numerous data were analyzed by the chi-square test. Two-sided tests were performed for all the statistical tests. In our study, 2 patients were lost in the follow-up in the L-ABZ group. One patient was lost in the follow-up in the T-ABZ group, and 1 patient was withdrawal from the study due to receiving surgery. Significant difference was identified in the 3-month TERs of L-ABZ group and T-ABZ group (33.3% vs 76.7%, P < 0.05). Also, remarkable difference was noted in the 6-month TERs in the L-ABZ group and T-ABZ group (66.7% vs 93.3%, P = 0.01). No statistical difference was noticed in the incidence rate of adverse reactions in both groups (P > 0.05). Based on our study, both T-ABZ and L-ABZ are effective for treating human CE. The TER in the L-ABZ group is superior to that of T-ABZ.


Assuntos
Albendazol/administração & dosagem , Anticestoides/administração & dosagem , Equinococose Hepática/tratamento farmacológico , Adolescente , Adulto , Idoso , Albendazol/efeitos adversos , Anticestoides/efeitos adversos , Feminino , Humanos , Lipossomos , Masculino , Pessoa de Meia-Idade , Comprimidos , Resultado do Tratamento , Adulto Jovem
2.
Artigo em Zh | MEDLINE | ID: mdl-12563861

RESUMO

AIM: To observe the histopathological changes of Echinococcus granulosus cysts in mice treated with liposomal albendazole and co-administration with cimetidine by light microscopy and electron microscopy. METHODS: An oral dose of liposomal ABZ with different formulations was given at 200 mg/kg.d. Cimetidine was administered daily at an oral dose of 100 mg/kg.d. Sixty-seven mice were orally given different drugs six days per week for a total of twelve weeks. RESULTS: The histopathological changes indicated that there were significant differences (P < 0.01) between treated groups and control group. The degeneration and necrosis of E. granulosus cysts were marked in liposomal albendazole combined with cimetidin group. CONCLUSION: Liposomal albendazole was more effective against E. granulosus cyst than albendazole. Cimetidine had an apparent synergistic effect when given in combination with liposomal albendazle.


Assuntos
Albendazol/farmacologia , Anticestoides/farmacologia , Echinococcus granulosus/efeitos dos fármacos , Lipossomos/administração & dosagem , Albendazol/administração & dosagem , Animais , Anticestoides/administração & dosagem , Cistos/tratamento farmacológico , Modelos Animais de Doenças , Sistemas de Liberação de Medicamentos , Echinococcus granulosus/ultraestrutura , Echinococcus multilocularis/efeitos dos fármacos , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Microscopia Eletrônica
3.
Med Parazitol (Mosk) ; (1): 52-5, 1999.
Artigo em Russo | MEDLINE | ID: mdl-10414050

RESUMO

The antiechinococcal activity of albendazole resynthesized at the E. I. Martsinovskii Institute of Medical Parasitology and Tropical Medicine was studied on infection models in rats and mouse in different experimental modifications. The efficiency of the therapy was determined in relation to the dose of the drug and its routes administrations, to the single or intermittent daily dose, to the presence or absence of intervals in the treatment regimen, to dosage forms. The trials indicated that albendazole was most active against larval alveolar echinococcosis of mice or cotton rats when it was used with their feed, i.e. through the gastrointestinal tract.


Assuntos
Albendazol/administração & dosagem , Anticestoides/administração & dosagem , Equinococose/tratamento farmacológico , Administração Oral , Administração Retal , Animais , Relação Dose-Resposta a Droga , Portadores de Fármacos , Avaliação Pré-Clínica de Medicamentos , Equinococose/parasitologia , Equinococose/patologia , Lipossomos , Camundongos , Camundongos Endogâmicos CBA , Sigmodontinae , Suspensões , Fatores de Tempo
4.
Cardiovasc Intervent Radiol ; 34 Suppl 2: S266-70, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20054546

RESUMO

A 27-year-old female with a type 2 hydatid cystic lesion in the liver according to the Gharbi classification (CE 3A according to the WHO classification) was referred for percutaneous treatment after albendazole treatment for 1 year. A catheterization technique was performed but hypertonic saline and alcohol were not given into the cavity due to cystobiliary leakage. During the 4-month follow-up period, sequential cavitography revealed biliary fistula, and bile-stained drainage had not been ceased despite the sphincterotomy, nasobiliary drainage catheter, and plastic stent. Since the patient refused to surgery, we embolized the biliary fistula using N-butyl 2-cyanoacrylate for the first time in the literature. At the 3-month follow-up, the patient's course was uneventful and ultrasound, multidetector-row CT, and MRI examinations revealed no collection in or adjacent to the cavity.


Assuntos
Fístula Biliar/terapia , Drenagem , Equinococose Hepática/terapia , Embolização Terapêutica/métodos , Embucrilato/administração & dosagem , Adesivos Teciduais/administração & dosagem , Adulto , Albendazol/administração & dosagem , Anticestoides/administração & dosagem , Fístula Biliar/diagnóstico , Terapia Combinada , Equinococose Hepática/diagnóstico , Feminino , Seguimentos , Humanos , Imageamento por Ressonância Magnética , Tomografia Computadorizada Espiral , Ultrassonografia
5.
Cardiovasc Intervent Radiol ; 34 Suppl 2: S260-5, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19847481

RESUMO

The aim of this case study is to present effectiveness of percutaneous drainage as a treatment option of ruptured lung and liver hydatid cysts. A 65-year-old male patient was admitted with complicated liver and lung hydatid cysts. A liver hydatid cyst had ruptured transdiaphragmatically, and a lung hydatid cyst had ruptured both into bronchi and pleural space. The patient could not undergo surgery because of decreased respiratory function. Both cysts were drained percutaneously using oral albendazole. Povidone-iodine was used to treat the liver cyst after closure of the diaphragmatic rupture. The drainage was considered successful, and the patient had no recurrence of signs and symptoms. Clinical, laboratory, and radiologic recovery was observed during 2.5 months of catheterization. The patient was asymptomatic after catheter drainage. No recurrence was detected during 86 months of follow-up. For inoperable patients with ruptured liver and lung hydatid cysts, percutaneous drainage with oral albendazole is an alternative treatment option to surgery. The percutaneous approach can be life-saving in such cases.


Assuntos
Fístula Brônquica/terapia , Diafragma , Drenagem/métodos , Equinococose Hepática/complicações , Equinococose Hepática/terapia , Equinococose Pulmonar/complicações , Equinococose Pulmonar/terapia , Derrame Pleural/terapia , Idoso , Albendazol/administração & dosagem , Anticestoides/administração & dosagem , Fístula Brônquica/diagnóstico , Terapia Combinada , Equinococose Hepática/diagnóstico , Equinococose Pulmonar/diagnóstico , Humanos , Masculino , Derrame Pleural/diagnóstico , Povidona-Iodo/administração & dosagem , Ruptura Espontânea/diagnóstico , Ruptura Espontânea/terapia , Escleroterapia , Irrigação Terapêutica , Tomografia Computadorizada por Raios X , Ultrassonografia
6.
J Helminthol ; 69(3): 213-21, 1995 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8522765

RESUMO

The parasite burden in the liver and peritoneal cavity, and antibody levels directed to whole worm extract, have been monitored in serum from ICR-strain mice, infected orally with 55 tetrathyridia of Mesocestoides corti (Cestoda, Cyclophyllidea). The subcurative does (3x or 6x) of praziquantel (PZQ) (10 mg.kg-1 body weight) were administered to mice from day 14 post infection (p.i.) in two drug formulations: as PZQ suspended in Dorfman vehicle, or as PZQ incorporated in liposomes (lip.PZQ). The appearance of antibodies was time-dependent and correlated with the rate of reduction in numbers of tetrathyridia. PZQ in three and six doses caused the highest fall of parasite numbers in the liver on day 1 post therapy (p.t.). In the peritoneal cavity, a similar reduction in worm burden occurred but only after six doses of the drug. The worm count in the peritoneal cavity from groups of mice injected with lip.PZQ decreased most markedly on day 7 p.t., in the group treated with six doses of the drug. In the liver, the highest larvicidal effect, compared with the controls, was observed 6 days later (i.e. day 13 p.t.), following three doses of lip.PZQ. In all treated groups, two peak values of antitetrathyridial antibody levels were detected between days 1 and 13 p.t. (i.e. days 17 to 29 p.i.), after which there was a gradual but continuous increase in antibody tire.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Anticorpos Anti-Helmínticos/sangue , Anticestoides/administração & dosagem , Infecções por Cestoides/tratamento farmacológico , Mesocestoides/imunologia , Praziquantel/administração & dosagem , Adjuvantes Imunológicos , Animais , Formação de Anticorpos/efeitos dos fármacos , Anticestoides/farmacologia , Infecções por Cestoides/imunologia , Infecções por Cestoides/parasitologia , Portadores de Fármacos , Lipossomos , Fígado/parasitologia , Camundongos , Camundongos Endogâmicos ICR , Cavidade Peritoneal/parasitologia , Praziquantel/farmacologia
7.
J Helminthol ; 77(3): 219-26, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12895280

RESUMO

The effects of glucan and liposomized glucan, alone or co-administered with vitamin C, and empty liposomes on hepatic fibrosis in mice infected with Mesocestoides corti (M. vogae) tetrathyridia were studied. Preparations were administered every third day from day 7 to day 31 post-infection (p.i.), nine doses in total. Activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and cholesterol levels were measured in sera collected on days 11, 15, 21, 28, 32, 42, 50 and 65 p.i. Liver fibrosis was studied on the same days by measuring hydroxyproline concentration, which is considered a marker for collagen content. Larvicidal effects of the glucan and liposome preparations were estimated on day 65 p.i. in the liver and peritoneal cavity. Glucan formulations significantly enhanced collagen content, most prominently after administration of liposomized glucan in combination with vitamin C. Activities of both enzymes and cholesterol levels were slightly modified after administration of glucan alone. Liposomized glucan with vitamin C significantly increased ALT and AST activity and cholesterol levels up to days 28-32 p.i., after which they plateaued or declined. The most pronounced decrease was after administration of liposomized glucan and vitamin C. The same pattern of biochemical parameters in serum was observed after administration of empty liposomes, however, collagen content was not modified significantly. Larval counts in the liver and the peritoneal cavity were significantly reduced after treatment with either glucan formulation, but were unaffected following treatment with empty liposomes. In summary, intense fibrosis in the liver of mice treated with liposomized glucan and vitamin C did not result in the most extensive parenchymal cell injury but, rather in the highest efficacy of treatment. Liposomal lipids were probably utilized in the reparation of the damaged parenchymal cells, while glucan stimulated phagocytic cells.


Assuntos
Anticestoides/uso terapêutico , Ácido Ascórbico/uso terapêutico , Infecções por Cestoides/tratamento farmacológico , Glucanos/uso terapêutico , Cirrose Hepática/tratamento farmacológico , Mesocestoides/isolamento & purificação , beta-Glucanas , Alanina Transaminase/sangue , Animais , Anticestoides/administração & dosagem , Aspartato Aminotransferases/sangue , Infecções por Cestoides/metabolismo , Infecções por Cestoides/parasitologia , Colágeno/metabolismo , Portadores de Fármacos , Quimioterapia Combinada , Glucanos/administração & dosagem , Lipossomos , Fígado/metabolismo , Cirrose Hepática/metabolismo , Cirrose Hepática/parasitologia , Masculino , Camundongos , Camundongos Endogâmicos ICR , Cavidade Peritoneal/parasitologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA